[go: up one dir, main page]

AU3632393A - Use of sydnonimines to treat erectile dysfunction - Google Patents

Use of sydnonimines to treat erectile dysfunction

Info

Publication number
AU3632393A
AU3632393A AU36323/93A AU3632393A AU3632393A AU 3632393 A AU3632393 A AU 3632393A AU 36323/93 A AU36323/93 A AU 36323/93A AU 3632393 A AU3632393 A AU 3632393A AU 3632393 A AU3632393 A AU 3632393A
Authority
AU
Australia
Prior art keywords
sydnonimines
erectile dysfunction
treat erectile
treat
dysfunction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU36323/93A
Inventor
Eckard Kujath
Karl Schonafinger
Christian Stief
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Cassella AG
Cassella Farbwerke Mainkur AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19924209462 external-priority patent/DE4209462A1/en
Priority claimed from DE19924213338 external-priority patent/DE4213338A1/en
Application filed by Cassella AG, Cassella Farbwerke Mainkur AG filed Critical Cassella AG
Publication of AU3632393A publication Critical patent/AU3632393A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU36323/93A 1992-03-24 1993-03-10 Use of sydnonimines to treat erectile dysfunction Abandoned AU3632393A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19924209462 DE4209462A1 (en) 1992-03-24 1992-03-24 Treatment of impotence
DE4209462 1992-03-24
DE19924213338 DE4213338A1 (en) 1992-04-23 1992-04-23 Treatment of impotence
DE4213338 1992-04-23

Publications (1)

Publication Number Publication Date
AU3632393A true AU3632393A (en) 1993-10-21

Family

ID=25913140

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36323/93A Abandoned AU3632393A (en) 1992-03-24 1993-03-10 Use of sydnonimines to treat erectile dysfunction

Country Status (2)

Country Link
AU (1) AU3632393A (en)
WO (1) WO1993018767A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4305881C1 (en) * 1993-02-26 1994-03-03 Lohmann Therapie Syst Lts Transdermal therapeutic system for topical and systemic application of active agents - includes cpd(s) from which nitrogen oxide is released by human or animal metabolism or cpds which release nitrogen oxide in organism
GB2339533A (en) * 1998-07-14 2000-02-02 James Martin Biggs Topical pharmaceutical preparations
CA2904539C (en) * 2013-03-15 2022-05-03 Melior Discovery, Inc. Methods of treating dyskinesia and related disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1496056A (en) * 1964-06-08 1967-09-29 Takeda Chemical Industries Ltd New chemical compounds of the sydnonimine type
DE1695897C3 (en) * 1966-07-04 1979-02-15 Takeda Chemical Industries Ltd N-acyl-sydnonimines, their salts, processes for their preparation and medicaments containing these compounds
DE1670127A1 (en) * 1966-08-09 1970-12-03 Boehringer Sohn Ingelheim Process for the preparation of new substituted 3-amino-sydnonimines
DE3702083A1 (en) * 1987-01-24 1988-08-04 Cassella Ag ALLYLMERCAPTOACETYL SYDNONIMINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE

Also Published As

Publication number Publication date
WO1993018767A1 (en) 1993-09-30

Similar Documents

Publication Publication Date Title
AU4199489A (en) Composition for the treatment of erectile dysfunction
AU2176592A (en) Methods of treating injury to the central nervous system
ZA938510B (en) Use of alpha-1C specific compounds to treat denign prostatic hyperplasia
AU7164987A (en) Treatment of sexual dysfunction with buspirone
GB9608408D0 (en) Treatment of erectile dysfunction
GB2266458B (en) Use of 3-hydroxypyridin-4-ones as selective therapeutics
PH20062A (en) Treatment of sexual dysfunction
EP1027057A4 (en) Treatment of female sexual dysfunction
ZA933519B (en) Treatment of wastewater
AU2160492A (en) Treatment of human diseases involving dysregulation or dysfunction of the nervous system
AU3007492A (en) Treatment of wastewater
TW236610B (en) Preparation of dinitrotoluene
IL124841A0 (en) Pge-1 containing lyophilized liposomes for use in the treatment of erectile dysfunction
AU3234995A (en) Use of il-6 to treat toxic shock
EP0413929A3 (en) Use of an ace-inhibitor to treat or prevent depression
EP0543902A4 (en) Use of metalloporphyrins to potentiate aids therapy
AU3477093A (en) 17beta -hydroxybenzoyl-4-aza-5alpha-androst-1-en-3-ones useful to treat baldness
GB2271579B (en) Treatment of wood
ZA931217B (en) Treatment of mineral tailings
AU4704797A (en) Use of benzopyranols to treat neurological disorders
AU4945297A (en) Pyrazolinones to treat disturbances of potency
HU9401833D0 (en) Use of renin inhibitors for the treatment of glaucoma
AU3632393A (en) Use of sydnonimines to treat erectile dysfunction
ZA93615B (en) Preparation of 2-amino-6-chloropurine
AU637873B2 (en) A method of treating erectile dysfunction